The latest price of evantumumab published on the entire network in 2024?

Evantumumab, developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is a targeted therapy for adult patients with non-small cell lung cancer carrying EGFR exon 20 insertion mutations. In May 2021, the drug was approved by the U.S. Food and Drug Administration (FDA), becoming the first NSCLC treatment targeting this specific mutation type. Through its unique dual mechanism of action, evantumumab targets both EGFR and MET receptors, effectively blocking the growth and spread signals of tumor cells and demonstrating significant anti-tumor activity.

Latest Price Overview

As of May 2024, the market pricing of shows obvious geographical differences. In mainland China, although evantuzumab has not yet been officially launched on the market, according to quotations from overseas drug purchase channels, the original drug of evantuzumab 350mg/7ml produced by Janssen Pharmaceuticals in the United States is priced at approximately $10,300. It should be noted that the prices of evantumumab are not static and may change due to exchange rate fluctuations, supply chain conditions, and different sales channels.

Purchasing channels and precautions

Since evantumumab has not yet been approved for marketing in mainland China, patients who need to use it currently mainly rely on overseas drug purchase channels. However, there are certain risks and challenges when choosing to purchase drugs overseas, including issues such as identification of drug authenticity, logistics costs, legal compliance, and subsequent medical support.

1. Consult a professional medical institution: Before considering using evantumumab, be sure to discuss it with a professional oncologist to evaluate whether the drug is suitable for your condition and how to obtain it safely.

2. Choose formal channels: ensure the legality and quality of drug sources through officially recognized overseas medical service institutions or cooperation with qualified international pharmacies.

3. Understand relevant policies: Be familiar with the relevant national laws and regulations on imported drugs for personal use, and apply for special import licenses when necessary.

4. Pay attention to medical insurance policies: Although evantumumab is currently not included in the medical insurance catalog, we continue to pay attention to the dynamics of medical insurance policies. It may be included in the scope of reimbursement in the future to reduce the burden on patients.

5. Financial assistance and charity projects: Pharmaceutical companies such as Johnson & Johnson often have patient assistance programs to provide financial support or drug donations to eligible patients, which deserves the attention of patients and their families.